Skip to content
value.today
Nephros, Inc. logo

Nephros, Inc.

NEPH
$36 Mmarket cap on Oct 30, 2026-6.5% since Jan 2024
Compare
World rank
#22,480
Revenue
$19 M
For year ending December-2025
Net income
$1 M
6.3% margin
SEC filing
Employees
36
As of December 31, 2025
SEC filing

Nephros, Inc. in brief

Nephros, Inc. is a listed company in the Medical Instruments industry, based in South Orange, New Jersey, USA. Its market value was $36 M on 30 October 2026, which makes it the 22,480th largest listed company in the world and the 3,991st largest in the USA on this site. In the year to December 2025 it had sales of $19 M and a net profit of $1 M, about 6 cents of profit for every dollar of sales. It employs about 36 people and Robert R. Banks Jr. is its chief executive. Its largest product and service lines by sales in 2025 were Royalty and Other Revenues (3%). Its shares trade under the symbol NEPH (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Nephros, Inc.

Nephros is a commercial-stage company that develops and markets high-performance water filtration solutions for points of use, with a core focus on medical-grade water filtration. Our medical filtration portfolio includes two product lines: infection control and dialysis water. The infection control segment features both microfilters (0.1 micron), which retain bacteria, and ultrafilters (0.005 micron), which retain bacteria, viruses, and endotoxins to address a broader spectrum of waterborne pathogens including and beyond Legionella and Pseudomonas. The dialysis segment consists exclusively of ultrafilters, extending the same microbial and endotoxin retention capabilities to the purification of water and bicarbonate concentrate used in dialysis treatment, where endotoxin control is especially critical. All of our medical-grade filters are FDA 510(k)-cleared as Class II medical devices—a distinguishing feature that affirms their validated safety and performance in critical-use environments. While these filters are widely used in healthcare settings, they have also been adopted across a range of other industries—including manufacturing, laboratories, aviation, and federal facilities—where water purity is essential to operational safety and compliance.

From the company's annual report filed with the US SEC: read the report

Nephros, Inc. timeline

2 events, 2002–2025
  1. 2002
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2025
  4. 💰
    Record revenue of $19 million
    FY2025, the highest of the 8 years on record.

Events of Nephros, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$23 M$46 M$69 M$92 M2020202120222023202420252026

World rank over time

▼ down 2,519 places since 2020
2020-01-01: #19989#19,98920202021-01-01: #18767#18,76720212022-01-07: #25564#25,56420222022-12-25: #31096#31,09620222023-07-30: #30465#30,46520232024-01-05: #26261#26,26120242026-03-08: #11195#11,19520262026-08-01: #19435#19,43520262026-10-30: #22508#22,5082026

Rank in USA: #3,868 (Jan 2020) · #3,785 (Jan 2021) · #4,824 (Jan 2022) · #5,529 (Dec 2022) · #5,293 (Jul 2023) · #4,179 (Jan 2024) · #2,180 (Mar 2026) · #3,736 (Aug 2026) · #3,994 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
18.7×
Price / sales (TTM)
1.6×
Price / book
3.5×
Free cash flow yield
-1.5%
Net margin (TTM)
8.8%
Operating margin
6.1%
Return on equity
18.6%
Liabilities / assets
25.2%
Net debt
$-4M
Revenue growth
+32.7%
R&D / revenue
7.1%
Revenue per employee
$522 K
Profit per employee
$33 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $6M, net income $-3M$6MFY18Fiscal year ending Dec 2019: revenue $10M, net income $-3M$10MFY19Fiscal year ending Dec 2020: revenue $9M, net income $-5M$9MFY20Fiscal year ending Dec 2021: revenue $10M, net income $-4M$10MFY21Fiscal year ending Dec 2022: revenue $10M, net income $-7M$10MFY22Fiscal year ending Dec 2023: revenue $14M, net income $-2M$14MFY23Fiscal year ending Dec 2024: revenue $14M, net income $0M$14MFY24Fiscal year ending Dec 2025: revenue $19M, net income $1M$19MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$19M+32.7%$1M$1M6.3%
Dec 2024$14M-0.6%$0M$0M0.5%
Dec 2023$14M+42.7%$-2M$-2M-11.1%
Dec 2022$10M-2.3%$-4M$-7M-71.2%
Dec 2021$10M+19.4%$-3M$-4M-37.9%
Dec 2020$9M-17.1%$-4M$-5M-52.9%
Dec 2019$10M+81.5%$-3M$-3M-30.8%
Dec 2018$6M—$-3M$-3M-59.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$2M——$0.11—
Dec 2024$-0M$0M$-1M$0.01—
Dec 2023$1M$0M$1M$-0.15—
Dec 2022$-3M$0M$-3M$-0.73—
Dec 2021$-1M$0M$-1M$-0.41—
Dec 2020$-7M$0M$-7M$-0.52—
Dec 2019$-2M$0M$-2M$-0.45—
Dec 2018$-4M——$-0.50—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$22M
Net income, trailing 12 months
$2M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $4M, net income $0M$4MDec ’24Three months to Mar 2025: revenue $5M, net income $1M$5MMar ’25Three months to Jun 2025: revenue $4M, net income $0M$4MJun ’25Three months to Sep 2025: revenue $5M, net income $0M$5MSep ’25Three months to Dec 2025 (from the annual report): revenue $5M, net income $0M$5MDec ’25Three months to Mar 2026: revenue $5M, net income $0M$5MMar ’26Three months to Jun 2026: revenue $6M, net income $1M$6MJun ’26Three months to Sep 2026: revenue $6M, net income $1M$6MSep ’26

Latest quarter to Sep 2026: revenue $6M (+18.1% on a year earlier), net income $1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Nephros, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$19 M
Operating income
$1 M
Net income
$1 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$14 M
Total liabilities
$3 M
Total equity
$10 M

As of December-2025

Nephros, Inc. products and services

Search all products and services →

Products (2)

  • Remove chlorine, taste, odor, cysts, chloramine, scale, soluble lead, and other particulates. Browse commercial water filtration solutions.

  • See Nephros dialysis water filters designed to maintain water quality, meet industry standards, and support safe, consistent patient care.

Services (6)

  • Nephros provides emergency water filtration support for bacteria-based water events and outbreaks, including suspected Legionella and other opportunistic waterborne pathogens. FDA Class II point-of-use fixture filters provide an immediate secondary barrier to support facility operations while longer-term mitigation plans are established.

  • Nephros provides expert installation and replacement support for infection control and commercial water filters to support proper installation, regulatory compliance, reliable system performance, and ongoing water safety.

  • Nephros provides ice machine audits for healthcare facilities to assess water sources, housings, tubing, maintenance practices, existing filtration, and opportunities to reduce waterborne contamination risks and improve water safety.

  • Nephros provides waterborne pathogen risk mitigation support through infection control filtration and water-quality education designed to reduce exposure to Legionella and other opportunistic waterborne pathogens in premise plumbing systems.

  • Nephros provides water management plan support for healthcare facilities through water system evaluations, facility audits, filtration solutions, and educational resources designed to support infection control, water safety, and operational continuity.

  • Nephros provides water safety and aesthetic improvement solutions using healthcare and commercial filtration technologies designed to address microbial contaminants and water-quality concerns such as taste, odor, cysts, scale, soluble lead, chlorine, chloramine, and E. Coli.

Top 36 institutional investors in Nephros, Inc.#

As of Sep 30, 2026
36 institutions held 2.6 M shares (about 23.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 19.3%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Nephros, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Topline Capital Management, LLC535,6980 (0.00%)4.93%$2 MNov 16, 2026
2Massachusetts Institute Of Technology346,813New3.19%$1 MNov 13, 2026
3Wexford Capital LP231,068-3,369,484 (-93.58%)2.13%$1 MNov 13, 2026
4Vanguard Capital Management LLC198,6430 (0.00%)1.83%$1 MNov 13, 2026
5Johns Hopkins University187,857New1.73%$1 MNov 16, 2026
6Meritage Group LP173,407New1.60%$1 MNov 13, 2026
7Morgan Stanley123,915-5,000 (-3.88%)1.14%$0 MNov 13, 2026
8Blackstone Inc.115,605New1.06%$0 MNov 16, 2026
9Bard Associates Inc115,528-2,475 (-2.10%)1.06%$0 MNov 13, 2026
10Renaissance Technologies LLC71,100-6,404 (-8.26%)0.65%$0 MNov 12, 2026
11Geode Capital Management, LLC70,2630 (0.00%)0.65%$0 MNov 6, 2026
12Mesirow Financial Investment Management, Inc.60,0000 (0.00%)0.55%$0 MNov 5, 2026
13HighTower Advisors, LLC59,7100 (0.00%)0.55%$0 MNov 10, 2026
14Essex Investment Management Co LLC38,9270 (0.00%)0.36%$0 MOct 19, 2026
15Vanguard Fiduciary Trust Co36,9010 (0.00%)0.34%$0 MNov 13, 2026
16Blair William & Co/il36,2490 (0.00%)0.33%$0 MNov 10, 2026
17Northern Trust Corp28,266+11,560 (+69.20%)0.26%$0 MNov 16, 2026
18Citadel Advisors LLC28,124-920 (-3.17%)0.26%$0 MNov 16, 2026
19Dimensional Fund Advisors LP22,1640 (0.00%)0.20%$0 MNov 4, 2026
20BlackRock, Inc.18,003-819 (-4.35%)0.17%$0 MNov 13, 2026
21State Street Corp15,6980 (0.00%)0.14%$0 MNov 12, 2026
22Mercer Global Advisors Inc /adv12,600+100 (+0.80%)0.12%$0 MNov 16, 2026
23Goldman Sachs Group Inc11,908-928 (-7.23%)0.11%$0 MNov 16, 2026
24Jasper Ridge Partners, L.P.11,560New0.11%$0 MNov 13, 2026
25Elkhorn Partners Limited Partnership11,0000 (0.00%)0.10%$0 MNov 13, 2026
Show all 36: investors 26 to 36
Institutional investors 26 to 36 in Nephros, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Cannell & Spears LLC11,0000 (0.00%)0.10%$0 MNov 12, 2026
27Bolton Securities Corporation7,192-19 (-0.26%)0.07%$0 MNov 12, 2026
28Royal Bank Of Canada1,061+234 (+28.30%)0.01%$0 MNov 16, 2026
29Wells Fargo & Company/mn200New0.00%$0 MNov 16, 2026
30Osaic Holdings, Inc.1750 (0.00%)0.00%$0 MNov 12, 2026
31SBI Securities Co., Ltd.154+4 (+2.67%)0.00%$0 MOct 22, 2026
32Tower Research Capital LLC (TRC)60New0.00%$0 MNov 16, 2026
33Harbour Investments, Inc.500 (0.00%)0.00%$0 MNov 9, 2026
34Jones Financial Companies Lllp31-196 (-86.34%)0.00%$0 MNov 13, 2026
35Barclays PLC23-4 (-14.81%)0.00%$0 MNov 6, 2026
36Citigroup Inc1New0.00%$0 MNov 4, 2026

Mutual funds holding Nephros, Inc.#

16 funds hold shares worth $1 M (about 2.0% of the company). Since their previous reports 4 added shares and 0 sold, buying $0 M net.
Mutual funds holding Nephros, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.130,901$0 M0.89%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.67,742$0 M0.46%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC33,707$0 M0.23%<0.01%+9.8%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors17,742$0 M0.12%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC11,571$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC9,528$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP4,811$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC3,085$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP3,337$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP2,725$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP2,462$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP2,333$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP2,332$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP1,419$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,080$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP409$0 M<0.01%<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 16 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Nephros, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$22 K
2 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$22 K
open market only
Insiders on file
26
since
$123 K$0Dec 2023: bought $40 K (1 trades), sold $0 (0 trades)Dec 23Mar 2024: bought $17 K (1 trades), sold $0 (0 trades)MarMay 2024: bought $123 K (3 trades), sold $0 (0 trades)MayNov 2026: bought $22 K (2 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Nephros, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Arthur H. AmronDirectorBuy+2,500$2.840$7 K169,637Form 4
filed Arthur H. AmronDirectorBuy+5,000$2.995$15 K167,137Form 4
filed Arthur H. AmronDirectorGrant or award+3,514——162,137Form 4
filed Oliver J. SpandowDirectorGrant or award+3,916——126,797Form 4
filed Amron Holdings LLCDirectorOther+17,749——158,623Form 4
filed Wexford GP LLC10% ownerOtherindirect-3.36 M——189,377Form 4
filed Amron Holdings LLCDirectorOtherindirect+2,836——2,836Form 4
filed Wexford GP LLC10% ownerOtherindirect-22,710$3.950$90 K166,667Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Nephros, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
11,913
0.1% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-05-08 13:57 UTC, code LUDP, resumed 14:02 UTC
  • 2025-09-09 13:30 UTC, code LUDP, resumed 13:35 UTC
  • 2025-06-20 19:53 UTC, code LUDP, resumed 20:00 UTC

Fails to deliver

  • : 1,430 shares at $3.27
  • : 144 shares at $4.47
  • : 121 shares at $4.52
  • : 1,509 shares at $4.55
  • : 1,317 shares at $3.51

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Nephros, Inc. scorecard#

Passes 12 of the 21 checks that could be worked out: strongest in growth (5 of 6), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation4 of 6
    • ✓P/E below its peers' median18.7×P/E 18.7× against Medical Instruments's median of 32.6×.
    • ✓Price to book below its peers' median3.5×Price to book 3.5× against Medical Instruments's median of 3.9×.
    • ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Medical Instruments's median of 3.0×.
    • ✗Free cash flow yield above 5%-1.6%Free cash flow is -1.6% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield5.3%Earnings yield 5.3% against the 10-year Treasury's 5.15% on 2026-11-13.
    • ✗The price assumes slower growth than the last three years'49.2%The price assumes 49.2% a year for ten years; revenue grew 23.5% a year over the last three.
  • Growth5 of 6
    • ✓Revenue grew in the newest year32.7%Revenue up 32.7% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years23.5%23.5% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median23.5%23.5% a year against Medical Instruments's median of 5.0% (37 companies).
    • ✓Earnings per share grew in the newest year0.11 vs 0.01Diluted EPS 0.11 in fiscal 2025 against 0.01 the year before (report's currency).
    • ✓Net income higher than five years earlier$1 M$1 M in fiscal 2025 against -$5 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability2 of 5
    • ✓Profitable in the newest year$1 MNet income $1 M in fiscal 2025.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median6.1%6.1% against Medical Instruments's median of 7.2% (46 companies).
    • ✗Return on equity above 15%12.7%12.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier6.1%6.1% in fiscal 2025 against -43.5% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities4.0×Current ratio 4.05 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-6.09Z-score -6.09 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year3.5%Diluted shares up 3.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Nephros, Inc.'s statements, beside the median of Medical Instruments.

Nephros, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin6.1%7.2%
Net margin6.3%3.8%
Return on equity12.7%3.5%
Revenue growth, 3 years a year23.5%5.0%
Revenue growth32.7%8.9%

6of 8on the Piotroski tests of financial strength

Nephros, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Nephros, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue19141410.010r8.6105.73.82.3
Cost of revenue7.25.45.85.24.6r3.64.32.51.51.0
Gross profit128.78.44.75.6r4.96.13.22.31.3
Research and development1.30.90.91.31.5r2.83.11.51.01.1
Selling, general and administrative9.07.78.97.67.2r6.56.14.53.32.9
Operating expenses108.710.09.18.9r9.29.26.24.54.2
Operating income1.10.0−1.6−4.3−3.3r−4.3−3.2−3.0−2.2−2.9
Interest and finance income———————0.00.00.0
Interest expense and finance costs0.00.00.00.00.00.10.20.20.30.2
Other non-operating income (expense)0.10.10.00.10.5−0.3r−0.1−0.0−0.10.0
Income before tax1.20.1−1.6——−4.5−3.4−3.4−2.6−3.0
Income tax0.00.0000—−0.2−0.1−1.8—
Income from discontinued operations———−2.8−1.1—————
Net income including minority interests——−1.6−7.1−3.9—−3.2−3.3−0.8−3.0
Minority interests' share of net income———0.30.2—0.20.1——
Net income attributable to shareholders1.20.1−1.6—−3.9−4.5−3.2r−3.4−0.8−3.0
Earnings per share, basic0.110.01-0.15-0.73-0.41-0.52-0.45-0.50r-0.02-0.06
Earnings per share, diluted0.110.01-0.15-0.73-0.41-0.52-0.45-0.50r-0.02-0.06
Shares, weighted average (basic)1111101010—————
Shares, weighted average (diluted)11111010109.17.56.8r5349
Balance sheet
Cash and cash equivalents5.43.84.33.67.08.24.24.62.20.3
Receivables2.41.81.51.31.61.41.01.4r0.80.4
Inventory3.22.62.53.24.5r5.32.61.90.70.5
Other current assets0.20.10.10.20.2r0.20.50.30.10.1
Current assets118.38.48.314158.38.23.81.3
Property, plant and equipment0.10.20.20.10.1r0.30.10.10.10.1
Right-of-use (leased) assets1.01.41.81.00.6r1.0r1.1———
Goodwill0.80.80.80.80.80.80.80.7——
Other intangible assets0.30.30.40.40.5r0.50.50.62.32.3
Total assets14111211181912115.02.7
Accounts payable0.90.60.90.71.30.41.00.80.90.6
Current liabilities2.81.62.11.42.41.32.42.71.90.9
Lease liabilities (non-current)0.71.01.40.7r0.3r0.7r0.9———
Total liabilities3.42.63.52.12.92.93.93.83.02.0
Retained earnings−143−144−144−143−136−132−127−124−121−120
Shareholders' equity——8.45.612134.73.82.00.7
Minority interests———3.33.13.13.03.0——
Total equity108.68.48.915167.76.82.00.7
Total liabilities and equity14111211181912115.02.7
Shares outstanding11111110109.98.17.2r5550
Cash-flow statement
Depreciation and amortization0.10.10.20.20.2r0.20.20.20.20.0
Share-based compensation0.30.21.11.01.30.81.31.00.80.6
Cash from operating activities1.6−0.50.8−3.2−1.4−6.9−2.3−3.7−0.1−2.1
Capital expenditure—−0.1−0.1−0.1−0.0−0.2−0.0——−0.0
Acquisitions, net of cash acquired——————−0.1−1.0——
Cash from investing activities0−0.1−0.1−0.1−0.1−0.2−0.2−1.0—−0.0
Debt issued—————0.5————
Shares issued—————112.03.81.2—
Cash from financing activities−0.0−0.0−0.10.00.2112.07.02.01.2
Change in cash1.6−0.50.7−3.3−1.34.1−0.42.4——
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Nephros, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$18 M97%
  • Royalty and Other Revenues$1 M3.0%
  • Service(total)$1 M2.8%
  • Other Revenue$0 M0.1%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Nephros, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$627 K
Andrew Astor
Other top executives, average
$323 K
the CEO earned 1.9× this
$100 invested is now
$25
Nephros, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Andrew Astor$627 K$1.2 M$323 K$25
2024Andrew Astor$410 K−$176 K$149 K$25
2023Robert R. Banks Jr.$695 K$1.3 M$168 K$40

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Nephros, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 4 · Material agreement 1 · Agreement ended 1 · Shareholder vote 2 · Results announced 10

Nephros, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Results announced8-K
Material agreementAgreement ended8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Nephros, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2021$1 MPrivate placement after listingUnder $2 million1equitySEC
May 2019$2 MPrivate placement after listing$2 to $10 million12equitySEC
Apr 2018$3 MPrivate placement after listing$2 to $10 million13equitySEC
Mar 2017$2 MPrivate placement after listing$2 to $10 million19equity, optionsSEC
Jul 2015$1 MPrivate placement after listingUnder $2 million1equitySEC
May 2015$1 MPrivate placement after listingUnder $2 million26equity, optionsSEC
Jul 2009$1 MNo. 1Under $2 million8equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Nephros, Inc. compares in Medical Instruments

  • Market cap$36 M · higher than 6% of 116
  • Revenue$19 M · higher than 8% of 120
  • Net margin8.8% · higher than 50% of 114
  • Revenue growth32.7% · higher than 96% of 49
  • P/E ratio18.7× · lower than 72% of 68
  • Price / sales1.6× · lower than 80% of 85
  • Price / book3.5× · lower than 51% of 84
  • FCF yield-1.6% · higher than 29% of 39

Peer comparison · Medical Instruments

CompanyMarket capP/ENet marginRev. growth
Nephros, Inc.🇺🇸$36 M18.7×8.8%+32.7%
Intuitive Surgical, Inc.🇺🇸$155.6 B52.6×25.5%+20.5%
EssilorLuxottica S.A.🇫🇷$88.0 B32.1×8.1%+4.5%
HOYA Corporation🇯🇵$56.2 B32.8×25.4%—
Becton, Dickinson and Company🇺🇸$54.0 B57.4×4.2%+8.2%
Alcon Inc.🇨🇭$37.1 B37.9×9.4%+4.9%
ResMed Inc.🇺🇸$35.3 B22.1×27.8%+9.8%
West Pharmaceutical Services, Inc.🇺🇸$27.1 B42.4×18.8%+6.3%
Terumo Corporation🇯🇵$24.9 B27.0×12.0%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Nephros, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Nephros, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Nephros, Inc.? Suggest a correction